Abstract
Proper coordination of inhalation and MDI canister activation is an important determinant of availability of medication to airways and subsequent clinical response. We compared coordination of terbutaline and pirbuterol MDIs by evaluating clinical effects, deposition in a model of the human upper airway, rate of aerosol settling in a tank, and particle size distribution. The maximum clinical effects and least deposition in the upper airway occurred when both MDIs were activated at onset of inhalation. When MDIs were activated before inhalation, pirbuterol was less affected than terbutaline. Pirbuterol MDI aerosol is slightly smaller than terbutaline MDI aerosol. The results of this study strongly suggest that both clinical and airway model differences noted were due, at least in part, to smaller size of pirbuterol aerosol.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
